Companies: 10,795·Total market cap: $144.5T
GT Biopharma, Inc.

GT Biopharma, Inc.

GTBPNASDAQHealthcare● Active
$0.41
$-0.01(-2.52%)
Market Cap$4402756
P/E Ratio
52W High$3.85
52W Low$0.261
SEC Filings

GT Biopharma, Inc. (GTBP) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000109657 · GTBP · NASDAQ · as of Jun 9, 2026

Filing snapshot

865
Total Filings
8-K
Latest Form
2026-05-22
Most Recent
2018
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0000109657 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-02
Fiscal Year End
Mar 2, 2026
Accession No.
0001493152-26-008443
Primary Document
form10-k.htm
Source: data.sec.gov · CIK 0000109657 · Accession 0001493152-26-008443

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
8-KCurrent Report
8-K
2026-05-22Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-05-22
View
10-QQuarterly Report
10-Q
2026-05-15
View
EFFECTEFFECT
EFFECT
2026-05-13
View
424B3424B3
424B3
2026-05-13
View
S-1IPO Registration Statement
S-1
2026-04-30
View
8-KCurrent Report
8-K
2026-04-07
View
10-Q/AQuarterly Report (Amended)
10-Q/A
2026-03-06
View
10-Q/AQuarterly Report (Amended)
10-Q/A
2026-03-06
View
10-KAnnual Report
10-K
2026-03-02
View
8-KCurrent Report
8-K
2026-03-02
View
EFFECTEFFECT
EFFECT
2026-01-30
View
424B3424B3
424B3
2026-01-30
View
CORRESPCORRESP
CORRESP
2026-01-28
View
UPLOADUPLOAD
UPLOAD
2026-01-27
View
S-1IPO Registration Statement
S-1
2026-01-21
View
Showing 1–15 of 751 filingsForm 4 / 144 hidden· 865 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000109657  |  Exchange: NASDAQ · Healthcare

GT Biopharma, Inc. (NASDAQ: GTBP) has submitted 865 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0000109657, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is GT Biopharma, Inc.'s most comprehensive regulatory disclosure. The most recent GT Biopharma, Inc. 10-K was filed on 2026-03-02 for fiscal year ending 2026. Historical GTBP 10-K annual reports are available from 1995 through 2026.

Investors researching GT Biopharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

GTBP SEC Filings · 8 questions

GT Biopharma, Inc. (GTBP) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 865 filings and access original documents at no cost. GT Biopharma, Inc.'s CIK is 0000109657.

GTBP SEC filingsGT Biopharma, Inc. SEC documentsfind GTBP 10-K